OncoMatch/Clinical Trials/NCT05740956
A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors
Is NCT05740956 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies HS-10502 for ovarian cancer.
Treatment: HS-10502 — HS-10502 is a Poly(ADP-ribose) polymerase 1 (PARP1)-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 in subjects with homologous recombination repair (HRR) gene mutant or homologous recombination deficiency (HRD) positive advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Breast Carcinoma
Pancreatic Cancer
Prostate Cancer
Colorectal Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard of care — failure or intolerance or not available
failure or intolerance or not available to the currently available Standard of care (SoC)
Cannot have received: PARP inhibitor
Exception: previous or current treatment with two or more
Previous or current treatment with two or more Poly(ADP-ribose) polymerase (PARP) inhibitors
Cannot have received: traditional Chinese medicine indicated for tumors
Exception: within 2 weeks prior to the first dose
Traditional Chinese medicine indicated for tumors within 2 weeks prior to the first dose of study treatment
Cannot have received: cytotoxic chemotherapeutic drugs
Exception: within 3 weeks before the first dose
Cytotoxic chemotherapeutic drugs, investigational drugs or other systematic anti-tumor therapies within 3 weeks before the first dose of study treatment
Cannot have received: nitrosourea
Exception: within 6 weeks prior to the first dose
Nitrosourea or Mitomycin C within 6 weeks prior to the first dose of study treatment
Cannot have received: Mitomycin C
Exception: within 6 weeks prior to the first dose
Nitrosourea or Mitomycin C within 6 weeks prior to the first dose of study treatment
Cannot have received: local radiotherapy
Exception: within 2 weeks prior to the first dose
Local radiotherapy within 2 weeks prior to the first dose of study treatment
Cannot have received: bone marrow radiotherapy or large-area irradiation
Exception: more than 30% of bone marrow radiotherapy or large-area irradiation within 4 weeks before the first dose
more than 30% of bone marrow radiotherapy or large-area irradiation within 4 weeks before the first dose of study treatment
Lab requirements
Blood counts
inadequate bone marrow reserve excluded
Kidney function
inadequate renal function excluded
Liver function
inadequate hepatic function excluded
Inadequate bone marrow reserve or hepatic and renal functions [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify